October 19, 2016—The Washington Post ran a profile of former House Energy & Commerce Chairman Henry Waxman (D-Calif.) last week pegged to his work to protect the 340B drug discount program. He also recently fielded questions from us about 340B and sky-high drug prices. Read on. … [Read more...]
Drug Prices Soar, Hospital Prices Barely Budge
October 14, 2016—Prescription drug prices rose 6.3 percent from August 2015 to August 2016, making them "easily the fastest growing price component" of U.S. healthcare spending, according to independent healthcare think tank Altarum Institute. Hospital-care price growth, meanwhile, held steady for a second year at 0.9 percent. … [Read more...]
Henry Waxman Can Pick His Causes. He Chooses to Fight for 340B.
October 12, 2016—Now that former House Energy & Commerce Chairman Henry Waxman is out of Congress and working as a lobbyist, he only represents clients he believes in. … [Read more...]
Hospitals Are Being Hammered by Rising Inpatient Drug Costs
October 11, 2016—Hospital spending on inpatient drugs is skyrocketing, including on old reliables such as the pain reliever acetaminophen and the antidiuretic vasopressin, a study from two leading hospital associations shows. … [Read more...]
Mylan Settles Over Bilking Medicaid, But No Word on 340B Refunds
October 11, 2016—Embattled EpiPen manufacturer Mylan has agreed to a $465 million settlement with the U.S. Justice Department to resolve claims the company underpaid Medicaid drug rebates by misclassifying EpiPen as a generic rather than brand-name product. It is unclear if the deal will compensate healthcare providers in the 340B drug discount program for Mylan overcharges. … [Read more...]
Audits Are Just One of the Ways HRSA Checks up on 340B Providers
October 7, 2016—The Health Resources and Services Administration audited 200 healthcare providers for compliance with 340B drug discount program requirements in the just-ended fiscal year, HRSA says. Audits are just one of the tools HRSA uses to make sure providers follow 340B's rules. … [Read more...]
An Idea MedPAC Should Take Off the Table
October 7, 2016—The Medicare Payment Advisory Commission continues to look at ways to put a lid on rising drug costs. MedPAC, which advises Congress on Medicare policy, has been meeting this week to continue discussions that began last year on changing how Medicare pays providers for drugs. MedPAC plans to make recommendations this spring. Reducing payment rates to hospitals in … [Read more...]